Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 11/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MPC2 | O95563 | 2/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867994 | 1.00 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| Potassium Ion SCHEMBL3867738 | 0.98 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| Potassium Ion SCHEMBL3867740 | 0.98 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL527388 | 0.88 | MAPT (0.54) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL17361063 | 0.88 | MAPT (0.54) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL1387126 | 0.88 | MAPT (0.54) | MAPTPPARGFFAR1PPARAMEN1 | |
| Hydrochloric Acid SCHEMBL3867753 | 0.87 | MAPT (0.53) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL1386640 | 0.85 | PPARG (0.53) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL526756 | 0.85 | PPARG (0.53) | MAPTPPARGFFAR1PPARAMEN1 | |
| Hydrochloric Acid SCHEMBL3871967 | 0.84 | PPARG (0.52) | MAPTPPARGFFAR1PPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | claimed |
| US-7521465-B2 | Diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | claimed |
| EP-1848700-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE]THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | Bexel Pharmaceuticals Inc (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006089225-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE] THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | claimed |
| US-20050288341-A1 | Novel diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | claimed |
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-7521465-B2 | Diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1848700-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE]THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | Bexel Pharmaceuticals Inc (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006089225-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE] THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20050288341-A1 | Novel diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288341-A1 | Novel diphenyl ether derivatives | GPR119, FABP4, PNLIP | PPARG 23/4885MAPT 3036/4885FFAR1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.